LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn about the safety and effectiveness of LAM-001 in
patients who have developed bronchiolitis obliterans syndrome (BOS), a form of chronic
rejection, after lung transplantation.
The main questions it aims to answer are:
- Is LAM-001 safe in these patients?
- Is LAM-001 effective in slowing BOS progression?
Participants will:
- Be randomly assigned to inhale either LAM-001 or placebo (a look-alike substance that
contains no active drug) daily for 48 weeks
- Attend 10 study visits (mixture of in-person and telehealth) over the 48 week period
- Undergo pulmonary function testing, bronchoscopy, lab testing, and physical examination
- Submit weekly home spirometry monitoring
Researchers will compare participants assigned to LAM-001 versus placebo to see if LAM-001 is
safely tolerated and to assess the effectiveness of LAM-001 on slowing BOS progression.